ConductScience.org, home

Paper36085147

Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.

Liu D and 8 others. Cell Discov, 2022. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs. Papers, record 36085147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36085147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs.
PubMed
Journal
Cell Discov
PubMed
Year
2022
PubMed
Publication types
Letter
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
1.19
iCite
Revised in PubMed
2022-09-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu DDengyuan
2Wu PPeng
3Gu WWentao
4Yang CCuihong
5Yang XXinmeng
6Deng XXingyu
7Xu JJun
8Jiang JJingmei
9Jiang CChengyu

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
81788101National Natural Science Foundation of China (National Science Foundation of China)PubMed
2021- I2M-1-022Chinese Academy of Medical Sciences (CAMS)PubMed
2021-CAMS-JZ001Chinese Academy of Medical Sciences (CAMS)PubMed
2021- I2M-1-062Chinese Academy of Medical Sciences (CAMS)PubMed

Source PubMed

Download CSV of grants

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125890286Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice.Part Fibre Toxicol2015https://conductscience.org/library/papers/25890286PubMed
225655897Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.Sci China Life Sci2015https://conductscience.org/library/papers/25655897PubMed
335405099Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial.Am Heart J2022https://conductscience.org/library/papers/35405099PubMed
432048163Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.Sci China Life Sci2020https://conductscience.org/library/papers/32048163PubMed
516007097A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.Nat Med2005https://conductscience.org/library/papers/16007097PubMed
631433752Angiotensin Type 1 Receptor Blockers in Heart Failure.Curr Drug Targets2020https://conductscience.org/library/papers/31433752PubMed
725391767Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury.Sci Rep2014https://conductscience.org/library/papers/25391767PubMed
833464336
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
JAMA2021https://conductscience.org/library/papers/33464336PubMed
934590760The inhibitory mechanisms of losartan and vitamin D on amiodarone-induced lung inflammation in rats: Role of mitogen-activated protein kinases/activator protein-1.J Biochem Mol Toxicol2021https://conductscience.org/library/papers/34590760PubMed

Download CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
40868984Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection.Int J Mol Sci2025https://conductscience.org/library/papers/40868984PubMed
40722848Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure.Biomedicines2025https://conductscience.org/library/papers/40722848PubMed
39599890Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses.Viruses2024https://conductscience.org/library/papers/39599890PubMed
38891966Structural Features Influencing the Bioactive Conformation of Angiotensin II and Angiotensin A: Relationship between Receptor Desensitization, Addiction, and the Blood-Brain Barrier.Int J Mol Sci2024https://conductscience.org/library/papers/38891966PubMed
38139391Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries.Int J Mol Sci2023https://conductscience.org/library/papers/38139391PubMed
37662725Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients.Heliyon2023https://conductscience.org/library/papers/37662725PubMed
37238657Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.Biomolecules2023https://conductscience.org/library/papers/37238657PubMed
37038324Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19.Pharmacol Res Perspect2023https://conductscience.org/library/papers/37038324PubMed
36864220Green fluorometric strategy for simultaneous determination of the antihypertensive drug telmisartan (A tentative therapeutic for COVID-19) with Nebivolol in human plasma.Sci Rep2023https://conductscience.org/library/papers/36864220PubMed
36835602Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.Int J Mol Sci2023https://conductscience.org/library/papers/36835602PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGT183PubTator's text mininghttps://conductscience.org/library/genes/183NCBI Gene
AGTR1185PubTator's text mininghttps://conductscience.org/library/genes/185NCBI Gene
REN5972PubTator's text mininghttps://conductscience.org/library/genes/5972NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36085147

GET https://conductscience.org/api/papers/v1/36085147/authors